Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 187 publications.
Pladelvall M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Kollhorst B, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a post authorisation safety study (PASS) in four European countries. Poster presented at the 31st ECNP Congress; October 8, 2018. Barcelona, Spain.
Herring WL, Zhang Y, Pearson I, Tempest M, Freudensprung U, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis (RRMS) in Scotland. Poster presented at the 2018 American Academy of Neurology Annual Meeting; April 22, 2018. Previously presented at the 7th Joint ECTRIMS-ACTRIMS Meeting.
Pladevall M, Hallas J, Schink T, Morros R, Poblador-Plou B, Forns J, Hellfritzsch M, Reinders T, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Pottegard A, Kollhorst B, Cortes J, Aguado J, Perlemuter G, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and risk of hospitalization for acute liver injury: nested case-control study in Spain, Germany, and Denmark. Poster presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE); August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):389.

Pages